Delivering on antimicrobial resistance agenda not possible without improving fungal diagnostic capabilities

Emerging Infectious Diseases

Volumn 23, Issue 2, 2017, Pages 177-183

  Denning, David W ^a,b,c   Perlin, David S ^a,d   Muldoon, Eavan G ^b,c   Colombo, Arnaldo Lopes ^a,e   Chakrabarti, Arunaloke ^a,f   Richardson, Malcolm D ^a,b,c   Sorrell, Tania C ^a,g  

^a Global Action Fund for Fungal Infections   (Switzerland)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLOSIS; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIAGNOSTIC ERROR; FUNGEMIA; HEALTH CARE; HOSPITAL; HUMAN; HUMAN CELL; HUMAN TISSUE; INTENSIVE CARE; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; MYCOSIS; PNEUMOCYSTIS; PREVALENCE; PUBLIC HEALTH; UNITED STATES; ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMORBIDITY; DISEASE EXACERBATION; DISEASE MANAGEMENT; DRUG EFFECTS; FUNGUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIXED INFECTION; PNEUMOCYSTIS PNEUMONIA; REPRODUCIBILITY; TUBERCULOSIS; VIROLOGY;

ANTIFUNGAL AGENT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIFUNGAL AGENTS; ASTHMA; COINFECTION; COMORBIDITY; DIAGNOSTIC ERRORS; DISEASE MANAGEMENT; DISEASE PROGRESSION; DRUG RESISTANCE, MICROBIAL; FUNGEMIA; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; PNEUMONIA, PNEUMOCYSTIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; TUBERCULOSIS;

EID: 85009961867     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2302.152042     Document Type: Article

References (50)

1. O’Neill J; The Review on Antimicrobial Resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. December 2014 [cited 2015 Aug 19]. http://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
2. The White House. National action plan for combating antibiotic-resistant bacteria. March 2015 [cited 2015 Aug 19]. https://www.whitehouse.gov/sites/default/files/docs/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf
3. World Health Organization. Antimicrobial resistance global report on surveillance 2014 [cited 2016 Apr 30]. http://www.who.int/drugresistance/documents/AMR_report_Web_slide_set.pdf
4. World Health Organization. Global action plan on antimicrobial resistance. 2015 [cited 2016 Feb 16]. http://www.wpro.who.int/entity/drug_resistance/resources/global_action_plan_eng.pdf
5. Yu VL. Guidelines for hospital-acquired pneumonia and health-care-associated pneumonia: a vulnerability, a pitfall, and a fatal flaw. Lancet Infect Dis. 2011;11:248-52. http://dx.doi.org/10.1016/S1473-3099(11)70005-6
6. Global Action Fund for Fungal Infections. Roadmap-executive summary. Improving outcomes for patients with fungal infections across the world: a road map for the next decade. May 2015 [cited 2015 May 10]. http://www.gaffi.org/roadmap/
7. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care. 2010;16:445-52. http://dx.doi.org/10.1097/MCC.0b013e32833e84d2
8. Tan BH, Chakrabarti A, Li RY, Patel AK, Watcharananan SP, Liu Z, et al.; Asia Fungal Working Group (AFWG). Incidence and species distribution of candidaemia in Asia: a laboratory-based surveillance study. Clin Microbiol Infect. 2015;21:946-53. http://dx.doi.org/10.1016/j.cmi.2015.06.010
9. Chen S, Slavin M, Nguyen Q, Marriott D, Playford EG, Ellis D, et al.; Australian Candidemia Study. Active surveillance for candidemia, Australia. Emerg Infect Dis. 2006;12:1508-16. http://dx.doi.org/10.3201/eid1210.060389
10. Giacomazzi J, Baethgen L, Carneiro LC, Millington MA, Denning DW, Colombo AL, et al.; Association with the LIFE Program. The burden of serious human fungal infections in Brazil. Mycoses. 2016;59:145-50. http://dx.doi.org/10.1111/myc.12427
11. Colombo AL, Nucci M, Park BJ, Nouér SA, Arthington-Skaggs B, da Matta DA, et al.; Brazilian Network Candidemia Study. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 2006;44:2816-23. http://dx.doi.org/10.1128/JCM.00773-06
12. Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. 2015;41:285-95. http://dx.doi.org/10.1007/s00134-014-3603-2
13. Kami M, Machida U, Okuzumi K, Matsumura T, Mori Si S, Hori A, et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol. 2002;117:40-6. http://dx.doi.org/10.1046/j.1365-2141.2002.03414.x
14. Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2011;49:665-70. http://dx.doi.org/10.1128/JCM.01602-10
15. Nguyen MH, Wissel MC, Shields RK, Salomoni MA, Hao B, Press EG, et al. Performance of Candida real-time polymerase chain reaction, β-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012;54:1240-8. http://dx.doi.org/10.1093/cid/cis200
16. Adams-Chapman I, Bann CM, Das A, Goldberg RN, Stoll BJ, Walsh MC, et al.; Eunice Kennedy Shriver National Institutes of Child Health and Human Development Neonatal Research Network. Neurodevelopmental outcome of extremely low birth weight infants with Candida infection. J Pediatr. 2013;163:961-7.e3. http://dx.doi.org/10.1016/j.jpeds.2013.04.034
17. Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, et al.; Israeli Candidemia Study Group. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother. 2012;56:2518-23. http://dx.doi.org/10.1128/AAC.05947-11
18. Pfaller MA, Castanheira M. Nosocomial candidiasis: antifungal stewardship and the importance of rapid diagnosis. Med Mycol. 2016;54:1-22.
19. Onishi A, Sugiyama D, Kogata Y, Saegusa J, Sugimoto T, Kawano S, et al. Diagnostic accuracy of serum 1,3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012;50:7-15. http://dx.doi.org/10.1128/JCM.05267-11
20. Martínez-Jiménez MC, Muñoz P, Valerio M, Vena A, Guinea J, Bouza E. Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment. J Antimicrob Chemother. 2015;70:3107-15. http://dx.doi.org/ 10.1093/jac/dkv241
21. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015;60:892-9. http://dx.doi.org/10.1093/cid/ciu959
22. Richardson R, Muldoon E. Compliance with candidaemia guidelines in the ICU-a UK tertiary referral teaching hospital experience. In: Abstracts of the European Conference on Clinical Microbiology and Infectious Diseases; Copenhagen, Denmark; 2015 Apr 25-27. Abstract P0215 [cited 2016 Apr 17]. https://www.escmid.org/escmid_publications/escmid_elibrary/?q=Compliance+with+candidaemia+guidelines+in+the+ICU%E2%80%93a+UK+t&id=2173&L=0&x=0&y=0
23. Walker B, Powers-Fletcher MV, Schmidt RL, Hanson KE. A cost-effectiveness analysis of multiplex PCR with magnetic resonance detection versus empiric or blood culture-directed therapy for the management of suspected candidemia. J Clin Microbiol. 2016;54:718-26. http://dx.doi.org/10.1128/JCM.02971-15
24. Ruhnke M. Antifungal stewardship in invasive Candida infections. Clin Microbiol Infect. 2014;20(Suppl 6):11-8. http://dx.doi.org/10.1111/1469-0691.12622
25. Chakaya J, Kirenga B, Getahun H. Long term complications after completion of pulmonary tuberculosis treatment: a quest for a public health approach. J Clin Tuberc Other Mycobact Dis. 2016;3:10-2. http://dx.doi.org/10.1016/j.jctube.2016.03.001
26. Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ. 2011;89:864-72. http://dx.doi.org/10.2471/BLT.11.089441
27. Sterling T, Jenkins C, Jayathilake K, Gotuzzo E, Veloso V, Cortes CP, et al. Culture-negative TB is associated with increased mortality in HIV-Infected persons. In: Abstracts of the Annual Conference on Retroviruses and Opportunistic Infections (CROI); Seattle, WA, USA; 2015 Feb 23-26. Abstract 833 [cited 2016 May 3]. http://www.croiconference.org/sessions/culture-negative-tb-associated-increased-mortality-hiv-infected-persons
28. Chu C-M, Woo PCY, Chong KTK, Leung WS, Chan VL, Yuen KY. Association of presence of Aspergillus antibodies with hemoptysis in patients with old tuberculosis or bronchiectasis but no radiologically visible mycetoma. J Clin Microbiol. 2004;42:665-9. http://dx.doi.org/10.1128/JCM.42.2.665-669.2004
29. Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, et al.; European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47:45-68. http://dx.doi.org/10.1183/13993003.00583-2015
30. Page ID, Richardson MD, Denning DW. Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA). J Infect. 2016;72:240-9. http://dx.doi.org/10.1016/j.jinf.2015.11.003
31. Dumollard C, Bailly S, Perriot S, Brenier-Pinchart MP, Saint-Raymond C, Camara B, et al. Prospective evaluation of a new Aspergillus IgG enzyme immunoassay kit for diagnosis of chronic and allergic pulmonary aspergillosis. J Clin Microbiol. 2016;54:1236-42. http://dx.doi.org/10.1128/JCM.03261-15
32. Ohba H, Miwa S, Shirai M, Kanai M, Eifuku T, Suda T, et al. Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med. 2012;106:724-9. http://dx.doi.org/ 10.1016/j.rmed.2012.01.014
33. Hedayati MT, Azimi Y, Droudinia A, Mousavi B, Khalilian A, Hedayati N, et al. Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran. Eur J Clin Microbiol Infect Dis. 2015;34:1759-65. http://dx.doi.org/10.1007/s10096-015-2409-7
34. World Health Organization. Global Tuberculosis Report 2014 [cited 2015 Mar 8]. http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf
35. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347-65. http://dx.doi.org/10.1164/rccm.201204-0596PP
36. López-Campos JL, Hartl S, Pozo-Rodriguez F, Roberts CM; European COPD Audit team. Antibiotic prescription for COPD exacerbations admitted to hospital: European COPD audit. PLoS One. 2015;10:e0124374. http://dx.doi.org/10.1371/journal.pone.0124374
37. Huerta A, Soler N, Esperatti M, Guerrero M, Menendez R, Gimeno A, et al. Importance of Aspergillus spp. isolation in Acute exacerbations of severe COPD: prevalence, factors and follow-up: the FUNGI-COPD study. Respir Res. 2014;15:17. http://dx.doi.org/10.1186/1465-9921-15-17
38. Guinea J, Torres-Narbona M, Gijón P, Muñoz P, Pozo F, Peláez T, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect. 2010;16:870-7. http://dx.doi.org/10.1111/j.1469-0691.2009.03015.x
39. Xu H, Li L, Huang WJ, Wang LX, Li WF, Yuan WF. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case control study from China. Clin Microbiol Infect. 2012;18:403-8. http://dx.doi.org/10.1111/j.1469-0691.2011.03503.x
40. Tan WC, Seale P, Ip M, Shim YS, Chiang CH, Ng TP, et al. Trends in COPD mortality and hospitalizations in countries and regions of Asia-Pacific. Respirology. 2009;14:90-7. http://dx.doi.org/10.1111/j.1440-1843.2008.01415.x
41. Lim S, Lam DC, Muttalif AR, Yunus F, Wongtim S, Lan TT, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. Asia Pac Fam Med. 2015;14:4. http://dx.doi.org/10.1186/s12930-015-0020-9
42. Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol. 2012;129:280-91, quiz 292-3. http://dx.doi.org/10.1016/j.jaci.2011.12.970
43. Lowe DM, Rangaka MX, Gordon F, James CD, Miller RF. Pneumocystis jirovecii pneumonia in tropical and low and middle income countries: a systematic review and meta-regression. PLoS One. 2013;8:e69969. http://dx.doi.org/10.1371/journal.pone.0069969
44. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1984;100:495-9. http://dx.doi.org/10.7326/0003-4819-100-4-495
45. Procop GW, Haddad S, Quinn J, Wilson ML, Henshaw NG, Reller LB, et al. Detection of Pneumocystis jiroveci in respiratory specimens by four staining methods. J Clin Microbiol. 2004;42:3333-5. http://dx.doi.org/10.1128/JCM.42.7.3333-3335.2004
46. Fan L-C, Lu H-W, Cheng K-B, Li HP, Xu JF. Evaluation of PCR in bronchoalveolar lavage fluid for diagnosis of Pneumocystis jirovecii pneumonia: a bivariate meta-analysis and systematic review. PLoS One. 2013;8:e73099. http://dx.doi.org/10.1371/journal.pone.0073099
47. Rafanan AL, Klevjer-Anderson P, Metersky ML. Pneumocystis carinii pneumonia diagnosed by non-induced sputum stained with a direct fluorescent antibody. Ann Clin Lab Sci. 1998;28:99-103.
48. Choe PG, Kang YM, Kim G, Park WB, Park SW, Kim HB, et al. Diagnostic value of direct fluorescence antibody staining for detecting Pneumocystis jirovecii in expectorated sputum from patients with HIV infection. Med Mycol. 2014;52:326-30. http://dx.doi.org/10.1093/mmy/myu002
49. Nowaseb V, Gaeb E, Fraczek MG, Richardson MD, Denning DW. Frequency of Pneumocystis jirovecii in sputum from HIV and TB patients in Namibia. J Infect Dev Ctries. 2014;8:349-57. http://dx.doi.org/10.3855/jidc.3864
50. Denning DW, Bromley MJ. Infectious Disease. How to bolster the antifungal pipeline. Science. 2015;347:1414-6. http://dx.doi.org/10.1126/science.aaa6097